Earnings beat lifts UPR.IR Uniphar plc EURONEXT: margin recovery ahead
UPR.IR stock jumped intraday to EUR 4.13 after Uniphar plc reported an earnings beat on 24 Feb 2026. The move follows stronger margins and a better-than-expected EPS of 0.24. Intraday range hit a high of EUR 4.19 and volume ran at 2,578,006 shares, well above the 50-day average of 392,514. We summarise the earnings drivers, price reaction on EURONEXT, and what the Meyka AI model now projects for the stock.
Earnings summary: UPR.IR stock
Uniphar reported an EPS of 0.24, beating consensus and prompting the intraday lift. Revenue per share stands at 10.91, and management flagged improved gross margins driven by the Product Access and Supply Chain divisions. The company confirmed the earnings announcement timing as 24 Feb 2026 and reiterated continued investment in specialist nursing and data services.
UPR.IR stock technicals and intraday move
Price traded between a low of EUR 3.90 and a high of EUR 4.19 on the session. Key technicals show RSI 60.54, ADX 34.46 indicating a strong trend, and Bollinger upper band near EUR 4.10. On balance volume (OBV) at 7,205,852 supports buyer interest. Short-term averages sit at EUR 3.71 (50-day) and EUR 3.79 (200-day).
Meyka AI rates UPR.IR with a score out of 100 and valuation view
Meyka AI rates UPR.IR with a score out of 100: 73.78 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst signals. Price/earnings sits at 16.65, EV/EBITDA at 13.30, and price-to-sales at 0.36. Debt to equity is 1.28, and current ratio is 0.95, which flags liquidity as a watch item. These grades are model outputs and not guaranteed; we are not financial advisors.
Revenue, margins and cash flow: UPR.IR analysis
Uniphar shows revenue per share of 10.91 and net income per share of 0.25 over the trailing twelve months. Operating cash flow per share is 0.29, but free cash flow per share is modest at 0.05. Net debt to EBITDA is 3.40, underlining leverage after strategic acquisitions. Gross margin improvement and a 43% year-on-year net income growth for FY 2024 support the positive earnings surprise.
Risks and opportunities for UPR.IR stock
Opportunity: Specialist nursing, infusion services, and data intelligence can sustain higher-margin growth and drive Product Access revenues. Risk: Working capital pressure is visible with a negative working capital of EUR -39,088,000.00 and days payables at 98.76, which leaves sensitivity to supplier terms and interest rates. Regulatory or contract risks in the UK and Ireland remain key watch items.
Analyst outlook, forecasts and UPR.IR stock price targets
Meyka AI’s forecast model projects a monthly price of EUR 4.42, quarterly EUR 4.81, and a 12-month model price of EUR 5.22. Versus the current price EUR 4.13, the 12-month projection implies an upside of 26.35%. The model also lists a 3-year projection of EUR 7.85 (implied upside 90.04%). Forecasts are model-based projections and not guarantees. For more context see Reuters coverage and company metrics source and the company profile source. For quick reference use our Meyka stock page Uniphar UPR.IR on Meyka.
Final Thoughts
UPR.IR stock reacted positively to the 24 Feb 2026 earnings beat, pushing the share price to EUR 4.13 on EURONEXT with above-average volume. Key strengths are margin recovery, a diversified three-division model and improving net income growth. Key weaknesses include elevated leverage with net debt to EBITDA at 3.40 and a tight current ratio near 0.95. Meyka AI’s forecast model projects a 12-month price of EUR 5.22, implying roughly 26.35% upside from today’s price. We present conservative and bullish scenario targets: conservative EUR 4.80, base EUR 5.22, and bullish three-year EUR 7.85. These figures aim to frame risk-reward for investors considering exposure to the healthcare distribution sector in Europe. Remember, Meyka AI grades and forecasts are model outputs and not guarantees, and this article is for informational purposes only.
FAQs
What drove the intraday move in UPR.IR stock today?
The intraday rise to EUR 4.13 followed Uniphar’s earnings beat on 24 Feb 2026. Stronger margins and a reported EPS of 0.24 plus higher-than-average volume of 2,578,006 shares drove the move.
What is Meyka AI’s outlook for UPR.IR stock?
Meyka AI’s forecast model projects a 12-month price of EUR 5.22, implying 26.35% upside from EUR 4.13. These are model-based projections and not guarantees.
Which risks should investors watch for UPR.IR stock?
Key risks include elevated leverage (net debt/EBITDA 3.40), tight liquidity (current ratio 0.95), and working capital strain with negative working capital. Regulatory or contract risks in core markets also matter.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.